MedTrace Logo

Lixisenatide for Restoration of Insulin Release in Subjects With Diabetes Mellitus Type 2

NCT00931372 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2012-02-23

No results posted yet for this study

Summary

The objective of this study is to test whether Lixisenatide (AVE0010) restores first phase and improves second phase insulin response in subjects with diabetes mellitus type 2.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Lixisenatide (AVE0010)

Solution for subcutaneous injection 100 µg/mL

DRUG

Placebo

Subcutaneous injection

Sponsors & Collaborators

  • Profil GmbH, Neuss, Germany

    collaborator UNKNOWN

  • Sanofi

    lead INDUSTRY

Principal Investigators

  • Christoph KAPITZA, MD · Profil GmbH, Neuss, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931372 on ClinicalTrials.gov